Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer

Table 2

Forest map of meta-analysis of patients’ efficiency among groups.

Study details	Experimental		Control		Weight (%)	Risk ratio
	Events	Total	Events	Total		MH, fixed, 95% CI
Si Feng, 2012	17	40	9	32	4.1	1.51 [0.78, 2.93]
Fu Hao, 2015	19	32	9	28	3.9	1.85 [1.00, 3.40]
Jian-Wu Liu, 2012	12	30	11	30	4.5	1.09 [0.57, 2.07]
Liu Tao, 2015	21	32	13	32	5.3	1.62 [0.99, 2.63]
Song Wenxian, 2018	16	30	10	30	4.1	1.60 [0.87, 2.94]
Yuan-yuan Zhang, 2014	14	31	9	28	3.8	1.41 [0.72, 2.73]
Xu Li, 2017	11	35	8	35	3.2	1.38 [0.63, 3.00]
Fang Li, 2017	14	23	7	23	2.8	2.00 [0.99, 4.03]
Li Lihua, 2016	13	23	9	23	3.7	1.44 [0.77, 5.69]
LuanWenQiang, 2012	11	25	7	27	2.7	1.70 [0.78, 3.69]
Relapsed Chicken, 2012	67	94	31	90	12.9	1.76 [1.27, 2.44]
Hi-Feng Wang, 2018	19	34	9	30	3.9	1.88 [1.00, 3.47]
Wang Fang, 2011	13	31	11	29	4.6	1.11 [0.59, 2.06]
Mention, 2010	9	20	2	20	0.8	4.50 [1.11, 18.27]
Xie Yanru, 2008	9	22	7	26	2.6	1.52 [0.68, 3.41]
Tany, 2013	21	38	12	38	4.9	1.75 [1.01, 3.03]
Xiao-jing Jia, 2017	6	20	4	20	1.6	1.50 [0.50, 4.52]
Deng Qingping, 2011	5	22	2	18	0.8	2.65 [0.59, 11.88]

Heterogeneity: chi² = 1.75, d_f = 2 ( = 0.42), and I² = 0%. Test for overall effect: Z = 1.23 ( = 0.22).